| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 540485000 |
Chalcogen double bonded directly to a ring carbon adjacent to the ring nitrogen (e.g., caprolactam, etc.)
| 161 |
| 540576000 |
Polycyclo ring system which contains the hetero ring as one of the cyclos
| 103 |
| 540553000 |
The hetero ring contains plural nitrogens (e.g., 1,3-diazepines, etc.)
| 97 |
| 540544000 |
The hetero ring contains chalcogen
| 63 |
| 540596000 |
Additional hetero ring attached directly or indirectly to the hetero ring by nonionic bonding
| 41 |
| 540543000 |
Spiro
| 9 |
| 540541000 |
Heavy metal or boron containing
| 6 |
| 540604000 |
Chalcogen attached directly to the hetero ring by nonionic bonding
| 6 |
| 540609000 |
Chalcogen or nitrogen attached indirectly to the hetero ring by acyclic nonionic bonding | 4 |
| 20090023917 | Selective Estrogen Receptor Modulators for the Treatment of Vasomotor Symptoms - The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause. | 01-22-2009 |
| 20150322024 | Cinnamic Acid Amide Derivative - The present invention provides a cinnamic acid amide derivative having an excellent analgesic action. The cinnamic acid amide derivative of the present invention is a compound showing excellent analgesic actions to not only a nociceptive pain model animal but also a neuropathic pain model animal, which is very useful as an agent for treating various pain diseases showing acute or chronic pains or neuropathic pains. | 11-12-2015 |
| 20140296517 | L-Setastine Hydrochloride and Preparation Method Thereof - The present invention relates to the field of medicine, and disclosed are an L-setastine hydrochloride and a preparation method therefor. The compound of the present invention has the advantages of stronger histamine Hi receptor antagonism and small side effect; the yield of the preparation method is more than 80%, and the product purity is high. The present invention also provides an application of the compound as an H1 histamine receptor antagonist. | 10-02-2014 |
| 20150057443 | Cycloalkyl Amine Compounds - Cycloalkyl amine compounds of Formula (I), | 02-26-2015 |
| 540542000 |
Phosphorus attached directly or indirectly to the hetero ring by nonionic bonding | 4 |
| 20120116074 | METHODS FOR THE PREPARATION OF [2-(8,9-DIOXO-2,6-DIAZABICYCLO[5.2.0]NON-1(7)-EN-2-YL)ETHYL]PHOSPHONIC ACID AND PRECURSORS THEREOF - The present invention is directed to processes associated with the preparation of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosphonic acid (perzinfotel). | 05-10-2012 |
| 20130253185 | NOVEL CATALYSTS - The present invention provides novel compounds and ligands that are useful in transition metal catalyzed cross-coupling reactions. For example, the compounds and ligands of the present invention are useful in palladium or gold catalyzed cross-coupling reactions. | 09-26-2013 |
| 20130274465 | ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS - Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminium salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form. | 10-17-2013 |
| 20160024024 | Novel Choline Kinase Inhibitors - This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds. | 01-28-2016 |
| 540605000 |
Nitrogen attached directly to the hetero ring by nonionic bonding | 3 |
| 20090253904 | Process for the Preparation of a Tetrahydro-1H-Azepines - The invention relates to an improved process for the preparation of a tetrahydro-1H-azepine of formula I | 10-08-2009 |
| 20090062530 | Substituted arylalkanoic acid derivatives and use thereof - A compound represented by the formula (I): | 03-05-2009 |
| 20110144329 | Amorphous Besifloxacin Solid - Amorphous solid-state form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 6.9-7.1, 9.4, 10.6-10.7, and 13.4-13.7°±0.2°, and a diffuse halo pattern at 11-30°; and (b) a DSC (differential scanning calorimetry) melting peak at about 267-272° C. The amorphous solid is prepared by rapid precipitation from a saturated or supersaturated solution of besifloxacin free base in a solvent comprising at least benzyl alcohol. | 06-16-2011 |
| 540607000 |
Having -C(=X)-, wherein X is chalcogen, bonded directly to nitrogen of the hetero ring | 2 |
| 20110009623 | SELECTIVE GROWTH OF STABLE POLYMORPHS - Methods and an apparatus for producing stable crystal polymorphs are provided. Inner surfaces of glass vials with a concave bottom topography are coated with nonstick compounds to select for nucleation of stable polymorphs. | 01-13-2011 |
| 20080207898 | PROCESSES FOR THE PREPARATION OF AMINOETHOXYBENZYL ALCOHOLS - The present invention provides processes and intermediates for the preparation of aminoethoxybenzyl alcohols of Formula I useful in the production of pharmaceutically useful compounds. | 08-28-2008 |
| 540612000 |
The hetero ring is unsubstituted or alkyl substituted only | 1 |
| 20140081019 | PROCESS FOR THE PREPARATION OF DEUTERATED COMPOUNDS CONTAINING N-ALKYL GROUPS - The present invention relates to a process for deuteration of amines in the alpha and/or beta position of the N-atom by using a deuterium source and a Ruthenium(II) based catalyst. | 03-20-2014 |
| 540611000 |
Benzene ring bonded directly to the hetero ring | 1 |
| 20120184735 | 2,3-DIHYDRO-1H-INDENE-2-YL UREA DERIVATIVE AND PHARMACEUTICAL APPLICATION OF SAME - A 2,3-dihydro-1H-indene-2-yl urea derivative represented by Formula (Ia) or a pharmaceutically acceptable salt thereof: | 07-19-2012 |
